Failed Experiment ReportMedicine
Andres S, Finch L, Iasonos A et al. · 2024 · Gynecologic oncology
Objective To determine the safety and efficacy of the oral progesterone antagonist onapristone extended release (onapristone-XR) in patients with recurrent progesterone receptor (PR)-positive adult-type granulosa cell tumor (aGCT),…
View details →DOI: 10.1016/j.ygyno.2024.06.026 Replication FailureOpen accessMedicine
Takagi K, Saito G, Tanaka H et al. · 2025 · ESMO open
Background The REMORA trial demonstrated efficacy and safety of lenvatinib in patients previously treated for advanced thymic carcinoma. However, more data regarding its use in clinical practice are required. Methods This multicenter…
View details →DOI: 10.1016/j.esmoop.2025.105301 Negative / Null Result ReportMedicine
Kerwin E, Dorinsky P, Patel M et al. · 2022 · The Journal of asthma : official journal of the Association for the Care of Asthma
Objective To evaluate the efficacy and safety of three doses of glycopyrrolate metered dose inhaler (GP MDI) in patients with uncontrolled asthma despite treatment with inhaled corticosteroid/long-acting β 2 -agonists (ICS/LABA) with or…
View details →DOI: 10.1080/02770903.2021.1938603 Negative / Null Result ReportOpen accessMedicine
Kirschner P, Konen FF, Axhausen F et al. · 2026 · Therapeutic advances in neurological disorders
Background B-cell depleting therapies (BCDT), including ocrelizumab, ofatumumab, and ublituximab, are highly effective disease-modifying therapies for multiple sclerosis (MS). Several case reports have raised concerns about new-onset or…
View details →DOI: 10.1177/17562864261427169 Negative / Null Result ReportMedicine
Lumish M, Chui MH, Zhou Q et al. · 2024 · Gynecologic oncology
Objective HER2 overexpression is associated with decreased overall survival in metastatic endometrial cancer. Trastuzumab with chemotherapy has demonstrated efficacy for first-line management of advanced HER2+ endometrial carcinoma, but…
View details →DOI: 10.1016/j.ygyno.2023.12.028 Negative / Null Result ReportOpen accessMedicine
Cecchini M, Kwiek B, Liu-Walsh F et al. · 2026 · Dermatology and therapy
Introduction Atopic dermatitis (AD) is a chronic, inflammatory skin disease with a high burden and unmet needs. Herein, we have assessed the efficacy and safety of JNJ-67484703, a programmed cell death protein 1 (PD-1)-agonizing/depleting…
View details →DOI: 10.1007/s13555-026-01746-6 Negative / Null Result ReportOpen accessMedicine
Chang JY, Balch C, Oh HS · 2024 · Viruses
Herpes simplex virus (HSV) has coevolved with Homo sapiens for over 100,000 years, maintaining a tenacious presence by establishing lifelong, incurable infections in over half the human population. As of 2024, an effective prophylactic or…
View details →DOI: 10.3390/v16091476 Negative / Null Result ReportMedicine
Sabha M, Siaton BC, Hochberg MC · 2020 · Expert opinion on investigational drugs
Introduction : Osteoarthritis (OA) is the most common form of arthritis. Knee OA is associated with joint pain, activity limitation, physical disability, reduced health-related quality of life, and increased mortality. To date, all…
View details →DOI: 10.1080/13543784.2020.1842357 Replication FailureOpen accessMedicine
Nagpal S, Nguyen KS, Bertrand S et al. · 2025 · Cancer reports (Hoboken, N.J.)
Background Brain metastases are common in patients with lung and breast cancer and are associated with poor outcomes. While there is some intracranial activity with systemic therapies, most chemotherapies are minimally effective.…
View details →DOI: 10.1002/cnr2.70330 Negative / Null Result ReportOpen accessMedicine
Lin CL, Chen MC, Lin CY et al. · 2026 · Journal of robotic surgery
Minimally invasive total mesorectal excision (TME) for rectal cancer can be performed via transanal TME (TaTME) or robotic TME (R-TME), yet comparative evidence in predominantly non-obese Asian cohorts remains limited. We evaluated a…
View details →DOI: 10.1007/s11701-026-03241-8 Replication FailureOpen accessMedicine
Miller RM, Nworu C, McKee L et al. · 2020 · Applied immunohistochemistry & molecular morphology : AIMM
Ataxia-telangiectasia mutated (ATM), a key activator of DNA damage response mechanisms, represents a potential biomarker for targeted gastric carcinoma therapies. A phase II study (Study 39; NCT01063517) designed to investigate the…
View details →DOI: 10.1097/pai.0000000000000786 Negative / Null Result ReportMedicine
Koch MW, Sage K, Kaur S et al. · 2021 · Neurology
Objective To assess whether treatment with the generic drug domperidone can reduce the progression of disability in secondary progressive multiple sclerosis (SPMS), we conducted a phase 2 futility trial following the Simon 2-stage design.…
View details →DOI: 10.1212/wnl.0000000000011863 Negative / Null Result ReportOpen accessMedicine
Wilky BA, Julian KA, Maleddu A et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Doxorubicin is standard chemotherapy for metastatic soft tissue sarcomas (STS) but also enhances innate/adaptive immune responses by inducing immunogenic cell death. Most STS are immune "cold" tumors that do not respond to immune…
View details →DOI: 10.1158/1078-0432.ccr-25-0618 Negative / Null Result Report
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Preprint
Abstract Purpose: We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations.…
View details →DOI: 10.21203/rs.3.rs-268461/v1 Negative / Null Result ReportMedicine
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Breast cancer research and treatment
Purpose We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations. Methods In…
View details →DOI: 10.1007/s10549-021-06292-7 Negative / Null Result ReportMedicine
Comi G, Dadon Y, Sasson N et al. · 2022 · Multiple sclerosis (Houndmills, Basingstoke, England)
Background Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS). Objective Evaluate laquinimod's efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS).…
View details →DOI: 10.1177/13524585211032803 Negative / Null Result ReportOpen accessMedicine
Manzo A, Sforza V, Carillio G et al. · 2022 · Frontiers in oncology
Few treatment options are available for patients with small cell lung cancer (SCLC) in progression after a first-line therapy. A novel therapeutic approach is represented by lurbinectedin, a synthetic derivative of trabectedin that works…
View details →DOI: 10.3389/fonc.2022.932105 Negative / Null Result ReportOpen accessMedicine
Schiphorst AT, Arquizan C, Turc G et al. · 2026 · Journal of stroke
Background and purpose Whether perfusion-diffusion mismatch modifies treatment effect of mechanical thrombectomy (MT) for large strokes is poorly known. To address this question, we conducted a post hoc secondary analysis of the Large…
View details →DOI: 10.5853/jos.2025.01200 Negative / Null Result ReportOpen accessMedicine
Levy A, Morel D, Texier M et al. · 2025 · Signal transduction and targeted therapy
Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable…
View details →DOI: 10.1038/s41392-025-02173-3 Negative / Null Result ReportOpen accessMedicine
Lenz HJ, Parikh A, Spigel DR et al. · 2024 · Journal for immunotherapy of cancer
Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in…
View details →DOI: 10.1136/jitc-2023-008409 Negative / Null Result ReportOpen accessMedicine
Pravisano F, Costa J, Marchi L et al. · 2026 · Cancers
The role of adjuvant therapy in stage III melanoma is well established in clinical practice. Because stage IIB-IIC melanoma carries a risk of recurrence and melanoma-specific mortality comparable to that of stage III disease, adjuvant…
View details →DOI: 10.3390/cancers18111802 Negative / Null Result ReportMedicine
Agnihotri G, Lio PA · 2020 · Clinical drug investigation
Multiple pathways contribute to the pathogenesis of atopic dermatitis (AD), and various targeted topical, biologic, and oral systemic agents have subsequently been developed. This review examines the mechanism of action and study designs…
View details →DOI: 10.1007/s40261-020-00905-7 Negative / Null Result ReportOpen accessMedicine
Geurts VCM, Voorwerk L, Balduzzi S et al. · 2023 · Breast (Edinburgh, Scotland)
The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die of this disease. Despite, relatively high levels of stromal tumor infiltrating lymphocytes…
View details →DOI: 10.1016/j.breast.2023.06.007 Failed Experiment ReportOpen accessMedicine
Da Cruz RS, Teague HL, Ramos-Benitez MJ et al. · 2026 · Critical care explorations
Objectives Understanding the mechanistic impact of fostamatinib, a spleen tyrosine kinase inhibitor, in severe COVID-19 using biomarkers associated with disease severity is crucial for the development of host-directed therapeutics. We…
View details →DOI: 10.1097/cce.0000000000001405 Failed Experiment ReportMedicine
Ishikawa M, Shibata T, Iwata T et al. · 2021 · Gynecologic oncology
Objective To assess the efficacy and safety of dose-dense weekly paclitaxel plus carboplatin (ddTC) with or without bevacizumab compared to conventional, tri-weekly paclitaxel plus carboplatin (cTC) with or without bevacizumab, in…
View details →DOI: 10.1016/j.ygyno.2021.05.007 Failed Experiment ReportOpen accessMedicine
Juárez-García M, Plasencia-Rodríguez C, Benavent D et al. · 2026 · Therapeutic advances in musculoskeletal disease
Background Axial spondyloarthritis (axSpA) is an inflammatory disease in which, despite expanding therapeutic options, a substantial proportion of patients do not achieve the desired treatment target, highlighting the emerging concept of…
View details →DOI: 10.1177/1759720x261456162 Negative / Null Result ReportMedicine
Rimel BJ, Enserro D, Bender DP et al. · 2024 · Cancer
Purpose This paper reports the efficacy of the poly (ADP-ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer.…
View details →DOI: 10.1002/cncr.35151 Negative / Null Result ReportMedicine
Marder G, Quach T, Chadha P et al. · 2024 · Rheumatology (Oxford, England)
Objective To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). Methods We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV…
View details →DOI: 10.1093/rheumatology/kead281 Negative / Null Result ReportOpen accessMedicine
White RA, Mezzano-Robinson V, Shi Q et al. · 2025 · The oncologist
Background The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic adenocarcinoma (PDAC) by inhibiting cancer stem cells and suppressing inflammatory cytokine…
View details →DOI: 10.1093/oncolo/oyaf162 Negative / Null Result ReportOpen accessMedicine
Zhang CD, Zhou JS, He LY et al. · 2025 · Frontiers in cardiovascular medicine
Objective The aim of this study was to investigate the quantitative flow ratio (QFR) outcomes in the left circumflex artery (LCX) following the placement of a crossover stent from the left main coronary artery (LM) to the left anterior…
View details →DOI: 10.3389/fcvm.2025.1578159 